Peptide-Coupled PLG Particles for Antigen-Specific Immune Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for inflammatory diseases and disorders, such as autoimmune diseases, face challenges including the need for long-term immunosuppressive drugs with toxic side effects, limited availability of source cells, and the complexity of antigen-specific therapies, which are costly and require precise antigen identification.
Innovation Solution
Development of antigen-coupled particles, particularly using poly(lactide-co-glycolide) (PLG) particles with a negative zeta potential, encapsulating or attaching antigens to induce antigen-specific tolerance, avoiding adverse events and eliminating the need for tissue-matched cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional broad-acting immunosuppressive drugs are used for long-term treatment, then immune suppression is achieved, but toxic side effects increase
Solution Approach 1:
The invention extracts the antigen-specific component from broad immunosuppression by using particles coupled with specific autoantigens (such as myelin basic protein, insulin, or glutamic acid decarboxylase). These particles selectively target and modulate immune responses against specific antigens while preserving overall immune function, thereby achieving immune suppression efficacy without the toxic side effects of conventional broad-acting drugs.
Solution Approach 2:
The patent employs carrier particles as intermediaries to deliver autoantigens to the immune system. These particles act as a mediator between the antigen and immune cells, facilitating antigen-specific tolerance induction. The particles can be internalized by antigen-presenting cells and processed to generate regulatory T cells, providing a controlled and specific immune modulation mechanism that avoids the non-specific toxicity of conventional drugs.
2Measurement precision
If antigen-specific therapies are developed, then treatment precision is improved, but manufacturing complexity and cost increase
Solution Approach 1:
The invention creates a universal platform using carrier particles that can be coupled with various autoantigens associated with different autoimmune diseases. The same basic particle technology and administration protocol can be applied across multiple diseases (such as multiple sclerosis, type 1 diabetes, and other autoimmune conditions), reducing the need for disease-specific complex therapies while maintaining antigen-specific precision.
Solution Approach 2:
The patent utilizes changes in particle parameters (such as size, charge, and composition) to optimize antigen delivery and immune modulation. By adjusting these physical and chemical parameters, the therapy achieves precise antigen-specific effects without requiring complex molecular engineering for each application, thereby simplifying manufacturing while maintaining precision.
3Reliability
If cell coupling methods are used for antigen-specific tolerance, then tolerance induction is achieved, but source cell availability is limited
Solution Approach 1:
The invention replaces the need for living donor cells with synthetic or semi-synthetic carrier particles that can be manufactured in large quantities through standardized processes. These particles serve as disposable, scalable alternatives to cell-based therapies, eliminating limitations related to donor availability, tissue typing, and cell culture requirements while maintaining antigen-specific tolerance induction efficacy.
Data Source
AI summary
The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).